Products & Services · Total Revenues
Opdivo Qvantig — Total Revenues
Bristol-Myers Squibb Opdivo Qvantig — Total Revenues increased by 123.3% to $67.00M in Q3 2025 compared to the prior quarter. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ1 2024
Last reportedQ3 2025
Rolls up toTotal Revenue
How to read this metric
An increase indicates strong market penetration and clinical demand for the therapy, while a decrease may signal increased competition from biosimilars or newer therapeutic alternatives.
Detailed definition
This metric represents the total net sales generated by the Opdivo product line, a cornerstone of the company's immuno-o...
Peer comparison
Comparable to revenue metrics for flagship oncology blockbusters at peer pharmaceutical companies, such as Keytruda for Merck or Tecentriq for Roche.
Metric ID:
bmy_segment_opdivo_qvantig_total_revenuesHistorical Data
6 periods
| Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $9.00M | $30.00M | $67.00M |
| QoQ Change | — | — | — | — | +233.3% | +123.3% |
Range$0.00 – $67.00M
Current Streak2+ quarters growth
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's opdivo qvantig — total revenues?
- Bristol-Myers Squibb (BMY) reported opdivo qvantig — total revenues of $67.00M in Q3 2025.
- What does opdivo qvantig — total revenues mean?
- The total revenue generated from sales of the Opdivo drug product.